News

Reach for Methotrexate in Refractory Cutaneous Lupus


 

EXPERT ANALYSIS FROM A SYMPOSIUM SPONSORED BY THE AMERICAN COLLEGE OF RHEUMATOLOGY

Topical therapy with corticosteroids and tacrolimus, a calcineurin inhibitor which is useful as a break from steroids, is also in place before she considers the introduction of systemic therapy starting with antimalarials.

To prevent lasting scarring in discoid LE patients with scalp involvement, Dr. Vleugels moves beyond systemic therapy, adding intralesional steroid injections. She typically takes triamcinolone (Kenalog) that comes in a concentration of 10 mg/cc, and dilutes it 1-to-1 with normal saline, for a final concentration of 5 mg/cc. She uses 0.1 cc of the diluted product per injection through a 30- or 31-gauge needle, picking the most inflamed areas of the scalp and placing the injections about 1 cm apart.

"One patient can tolerate only about 25 injections per day, sometimes fewer than that," Dr. Vleugels said, eliciting audience gasps. "You’d be surprised: Even our kids with scalp disease can tolerate injections fairly well because of the very small needle we use."

She has the patient return for another series of scalp injections in 5-6 weeks.

Dr. Vleugels reported having no financial conflicts.

Pages

Recommended Reading

Low-Dose IL-2 Induced HCV Vasculitis Remission
MDedge Rheumatology
Early Detection of Scleroderma-Associated PAH Enhanced Survival
MDedge Rheumatology
Vardenafil Increased Blood Flow in Raynaud Syndrome
MDedge Rheumatology
B Cells Key in Takayasu Arteritis
MDedge Rheumatology
Antiphospholipid Syndrome Plus Miscarriage Ups Clot Risk
MDedge Rheumatology
Preterm Delivery a Risk in Systemic Sclerosis
MDedge Rheumatology
Ondansetron Quells Methotrexate-Induced Nausea
MDedge Rheumatology
JSLE Imparts Severe Organ Involvement
MDedge Rheumatology
Obesity Epidemic Is Skewing Face of Gout
MDedge Rheumatology
Pegloticase Safe as Induction Therapy in Tophaceous Gout
MDedge Rheumatology